Novavax reports Q2 revenue and updates 2026 guidance
Novavax reported $57M revenue and upwardly revised its 2026 revenue guidance driven by potential earnings from a Sanofi combination trial and existing collaborations. Sentiment reflects a shift toward positive operational visibility.
View filing at SEC.gov →